165 related articles for article (PubMed ID: 19773444)
1. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
2. Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.
Mimeault M; Johansson SL; Batra SK
Br J Cancer; 2013 Mar; 108(5):1079-91. PubMed ID: 23449353
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
4. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
5. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
7. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
[TBL] [Abstract][Full Text] [Related]
8. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Hishida S; Kawakami K; Fujita Y; Kato T; Takai M; Iinuma K; Nakane K; Tsuchiya T; Koie T; Miura Y; Ito M; Mizutani K
Prostate; 2021 Jun; 81(9):592-602. PubMed ID: 33905554
[TBL] [Abstract][Full Text] [Related]
10. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
Zhang HL; Yang LF; Zhu Y; Yao XD; Zhang SL; Dai B; Zhu YP; Shen YJ; Shi GH; Ye DW
Prostate; 2011 Feb; 71(3):326-31. PubMed ID: 20842666
[TBL] [Abstract][Full Text] [Related]
11. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.
Uzoh CC; Holly JM; Biernacka KM; Persad RA; Bahl A; Gillatt D; Perks CM
Br J Cancer; 2011 May; 104(10):1587-93. PubMed ID: 21487405
[TBL] [Abstract][Full Text] [Related]
13. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Mahon KL; Sutherland SI; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG
Prostate; 2024 Jun; 84(8):747-755. PubMed ID: 38544345
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
15. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
Shi GH; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Xiao WJ; Ma CG
Acta Pharmacol Sin; 2010 Jul; 31(7):867-73. PubMed ID: 20581857
[TBL] [Abstract][Full Text] [Related]
16. [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Olbert PJ; Weil C; Hegele A; Hofmann R; Schrader AJ
Aktuelle Urol; 2009 May; 40(3):164-8. PubMed ID: 19370533
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Desarnaud F; Geck P; Parkin C; Carpinito G; Makarovskiy AN
Cancer Biol Ther; 2011 Jan; 11(2):204-12. PubMed ID: 21057205
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
20. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Al Nakouzi N; Cotteret S; Commo F; Gaudin C; Rajpar S; Dessen P; Vielh P; Fizazi K; Chauchereau A
Oncotarget; 2014 Feb; 5(3):667-78. PubMed ID: 24525428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
